Rivastigmine is a reversible non-competitive inhibitor of acetylcholinesterase which first received marketing authorisation in 1998 [57] and is currently licensed for use in Alzheimer’s dementia and Parkinson’s dementia [52]. This evidence concerns the gene ACHE and Alzheimer disease.